{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:06:28Z","timestamp":1788051988563,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-820","type":"journal-article","created":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T03:01:22Z","timestamp":1415329282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":152,"title":["Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Xichun","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"issue":"2","key":"5005_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/ije\/dyh414","volume":"34","author":"MD Althuis","year":"2005","unstructured":"Althuis MD, Dozier JD, Anderson WF, Devesa SS, Brinton LA: Global trends in breast cancer incidence and mortality 1973\u20131997. Int J Epidemiol. 2005, 34 (2): 405-412. 10.1093\/ije\/dyh414. Epub 2005 Feb 28","journal-title":"Int J Epidemiol"},{"issue":"9472","key":"5005_CR2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005, 365 (9472): 1687-1717.","journal-title":"Lancet"},{"key":"5005_CR3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/ncponc0905","volume":"4","author":"S Banerjee","year":"2007","unstructured":"Banerjee S, Dowsett M, Ashworth A, Martin LA: Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol. 2007, 4: 536-550.","journal-title":"Nat Clin Pract Oncol"},{"key":"5005_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N: Vascular endothelial growth factor basic science and clinical progress. Endocr Rev. 2004, 25: 581-611. 10.1210\/er.2003-0027.","journal-title":"Endocr Rev"},{"key":"5005_CR5","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY, Cort\u00e9s J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010, 28: 3239-3247. 10.1200\/JCO.2008.21.6457.","journal-title":"J Clin Oncol"},{"key":"5005_CR6","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007, 357: 2666-2676. 10.1056\/NEJMoa072113.","journal-title":"N Engl J Med"},{"key":"5005_CR7","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Di\u00e9ras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor r 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011, 29: 1252-1260. 10.1200\/JCO.2010.28.0982.","journal-title":"J Clin Oncol"},{"issue":"32","key":"5005_CR8","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"AM Brufsky","year":"2011","unstructured":"Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS: RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011, 29 (32): 4286-4293. 10.1200\/JCO.2010.34.1255. Epub 2011 Oct 11","journal-title":"J Clin Oncol"},{"issue":"24","key":"5005_CR9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006, 355 (24): 2542-2550. 10.1056\/NEJMoa061884.","journal-title":"N Engl J Med"},{"issue":"9605","key":"5005_CR10","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N: AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007, 370 (9605): 2103-2111. 10.1016\/S0140-6736(07)61904-7.","journal-title":"Lancet"},{"issue":"23","key":"5005_CR11","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350 (23): 2335-2342. 10.1056\/NEJMoa032691.","journal-title":"N Engl J Med"},{"issue":"26","key":"5005_CR12","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX, Gynecologic Oncology Group: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011, 365 (26): 2473-2483. 10.1056\/NEJMoa1104390.","journal-title":"N Engl J Med"},{"issue":"1","key":"5005_CR13","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascularendothelial growth factor and platelet-derived growth factor receptors: determination of apharmacokinetic\/ pharmacodynamic relationship. Clin Cancer Res. 2003, 9 (1): 327-337.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5005_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006, 5 (10): 835-844. 10.1038\/nrd2130.","journal-title":"Nat Rev Drug Discov"},{"key":"5005_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/CAD.0b013e32832b2ea0","volume":"20","author":"G Bianchi","year":"2009","unstructured":"Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Pe\u00f1a C, Lathia C, Bergamini L, Gianni L: Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009, 20: 616-624. 10.1097\/CAD.0b013e32832b2ea0.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"5005_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.2007.15.5242","volume":"27","author":"A Moreno-Aspitia","year":"2009","unstructured":"Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA: Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009, 27 (1): 11-5. Epub 2008 Dec 1","journal-title":"J Clin Oncol"},{"key":"5005_CR17","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","volume":"26","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008, 26: 1810-1816. 10.1200\/JCO.2007.14.5375.","journal-title":"J Clin Oncol"},{"key":"5005_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/1471-2407-10-529","volume":"10","author":"J Li","year":"2010","unstructured":"Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, Zheng C, Zuo Y: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010, 10: 529-10.1186\/1471-2407-10-529.","journal-title":"BMC Cancer"},{"issue":"26","key":"5005_CR19","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","volume":"31","author":"J Li","year":"2013","unstructured":"Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H: Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013, 31 (26): 3219-3225. 10.1200\/JCO.2013.48.8585.","journal-title":"J Clin Oncol"},{"key":"5005_CR20","volume-title":"Int J Cancer","author":"X Hu","year":"2014","unstructured":"Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, Fan M, Li J, Wang B, Wang Z, Zhang Q, Sun S, Liao C: Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014, Epub ahead of print"},{"issue":"2","key":"5005_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007, 356 (2): 125-134. 10.1056\/NEJMoa060655.","journal-title":"N Engl J Med"},{"issue":"4","key":"5005_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359 (4): 378-390. 10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"issue":"5 Suppl 16","key":"5005_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","volume":"30","author":"MA Cobleigh","year":"2003","unstructured":"Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A: A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003, 30 (5 Suppl 16): 117-124.","journal-title":"Semin Oncol"},{"key":"5005_CR24","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1200\/JCO.2011.36.7771","volume":"30","author":"J Baselga","year":"2012","unstructured":"Baselga J, Segalla JG, Roch\u00e9 H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, G\u00f3mez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Dur\u00e1n M\u00c1, Hoff PM, Espi\u00e9 M, de Moraes AA, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S, Costa F: Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol. 2012, 30: 1484-1491. 10.1200\/JCO.2011.36.7771.","journal-title":"J Clin Oncol"},{"issue":"10","key":"5005_CR25","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1158\/1078-0432.CCR-12-3177","volume":"19","author":"LS Schwartzberg","year":"2013","unstructured":"Schwartzberg LS, Tauer KW, Hermann RC, Makari-Judson G, Isaacs C, Beck JT, Kaklamani V, Stepanski EJ, Rugo HS, Wang W, Bell-McGuinn K, Kirshner JJ, Eisenberg P, Emanuelson R, Keaton M, Levine E, Medgyesy DC, Qamar R, Starr A, Ro SK, Lokker NA, Hudis CA: Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negativeadvanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 2013, 19 (10): 2745-2754. 10.1158\/1078-0432.CCR-12-3177.","journal-title":"Clin Cancer Res"},{"key":"5005_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ejca.2012.08.005","volume":"49","author":"WJ Gradishar","year":"2013","unstructured":"Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Ro SK, Lokker NA, Schwartzberg L: A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer. 2013, 49: 312-322. 10.1016\/j.ejca.2012.08.005.","journal-title":"Eur J Cancer"},{"issue":"Suppl 2","key":"5005_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0959-8049(11)70116-2","volume":"47","author":"G Mariani","year":"2011","unstructured":"Mariani G, Burdaeva O, Roman L, Staroslawska E, Udovitsa D, Driol P, Goisis G, Zamagni C, Semiglazov V, Gianni L: A double-blind, randomized phase IIb study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with docetaxel and\/or letrozole in patients with metastatic breast cancer (MDC): FM-B07-01 Trial [abstract]. Eur J Cancer. 2011, 47 (Suppl 2): 10-","journal-title":"Eur J Cancer"},{"issue":"18","key":"5005_CR28","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1200\/JCO.2010.31.2975","volume":"29","author":"HS Rugo","year":"2011","unstructured":"Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D: Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011, 29 (18): 2459-2465. 10.1200\/JCO.2010.31.2975.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5005_CR29","doi-asserted-by":"publisher","first-page":"L344","DOI":"10.1152\/ajplung.00291.2003","volume":"287","author":"JR Tang","year":"2004","unstructured":"Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsella JP, Abman SH: Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol. 2004, 287 (2): L344-51. 10.1152\/ajplung.00291.2003.","journal-title":"Am J Physiol Lung Cell Mol Physiol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-820.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-820\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T17:58:26Z","timestamp":1468346306000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["5005"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-820","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,7]]},"article-number":"820"}}